Human Growth Hormone Market Set to Reach US$ 7.3 Billion by 2032

Trishita Deb
Trishita Deb

Updated · Jan 8, 2025

SHARE:

Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Introduction

The Global Human Growth Hormone Market is projected to grow from USD 3.4 billion in 2022 to USD 7.3 billion by 2032, at a CAGR of 8.1% during the forecast period. This growth is driven by advancements in treatment options, regulatory approvals, strategic collaborations, increased awareness, and innovations in drug delivery technologies.

Recent developments in hGH therapies have revolutionized treatment options. The U.S. FDA approved Pfizer’s NGENLA™ in June 2023, offering a once-weekly injection for pediatric growth hormone deficiency. Similarly, Sogroya (somapacitan), approved in 2020, introduced the first once-weekly hGH therapy for adults. These advancements enhance patient adherence and convenience, bolstering market growth.

Collaborations among pharmaceutical companies have expedited hGH innovation. Pfizer and OPKO Health, for instance, partnered to develop long-acting hGH therapies, leveraging combined expertise. Simultaneously, improved diagnostic techniques and greater awareness of growth hormone deficiencies are increasing early diagnoses and treatment adoption, further driving market demand.

Innovative drug delivery technologies, such as auto-injectors and pen devices, are improving patient compliance and comfort. These advancements make treatments more user-friendly, expanding accessibility for patients and supporting the market’s growth trajectory.

Human Growth Hormone Market

Key Takeaways

  • The Human Growth Hormone (HGH) market is forecasted to grow at a CAGR of 8.1%, reaching USD 7.3 billion by 2032.
  • The market was valued at USD 3.4 billion in 2022, with significant expansion expected over the next decade.
  • Powder-form HGH dominated product sales in 2022, contributing 56.5% of the total market share.
  • Growth hormone deficiency was the leading indication for HGH use during the forecast period of 2023 to 2032.
  • In 2022, parenteral administration (injection) emerged as the most common delivery method for HGH treatments.
  • North America led the HGH market in 2022, holding the largest regional market share of 37.4%.
  • Asia-Pacific accounted for a significant 23.7% market share in 2022, reflecting its growing importance in the HGH industry.
  • HGH, also known as somatotropin, is a critical hormone that stimulates growth and development in the body.
  • Genetic disorders like Turner syndrome and Prader-Willi syndrome are primary contributors to HGH deficiency in patients.
  • Market growth is driven by innovations in HGH products and rising awareness of synthetic HGH therapies worldwide.
  • Online pharmacies are increasingly popular as a channel for HGH sales, enhancing convenience and accessibility for consumers.
  • Challenges include economic constraints in developing countries and strict regulations on HGH use, especially in sports.
  • India and China present significant growth opportunities due to their large populations and expanding healthcare markets.
  • Key players in the HGH market include pharmaceutical giants like Pfizer, Merck, and other prominent companies driving innovation and distribution.

Regional Analysis

North America held a 37.4% share of the global human growth hormone market. This dominance is due to favorable reimbursement policies and well-established healthcare infrastructure. Increasing healthcare awareness among the population further drives market growth in this region. These factors create an environment conducive to innovation and the adoption of advanced medical solutions.

The U.S. plays a vital role in driving growth within North America. The availability of innovative pharmaceuticals boosts the market. This is supported by the presence of key industry players operating in the country. Additionally, the rising geriatric population and higher healthcare spending strengthen the market. These dynamics make the U.S. a major contributor to North America’s dominance.

Asia-Pacific is expected to witness the highest growth during the forecast period. The region offers substantial opportunities for market players due to increasing adoption of new products. Countries like China and Japan are pivotal to this growth. Companies are focusing on these markets to capture a larger share. Rising healthcare investment in the region adds to the market’s potential.

Key players are adopting strategies to penetrate the Asia-Pacific market effectively. They are introducing innovative solutions and establishing partnerships. This focus on emerging economies is driven by rising demand for advanced pharmaceuticals. Market players are also leveraging growing healthcare awareness in APAC. Such efforts are expected to drive significant revenue growth in the region during the forecast period.

Emerging Trends

  • Long-Acting HGH Formulations: The development of long-acting HGH formulations is transforming the market. Unlike daily injections, these treatments require less frequent dosing, offering improved convenience for patients. This innovation is expected to dominate the market in countries like the U.S., Germany, and Japan. By 2030, long-acting formulations could capture over 90% of the market share in these regions. The shift is driven by better patient compliance and a reduced treatment burden, making it a game-changer in HGH therapy.
  • HGH in Anti-Aging Therapies: There is growing interest in HGH for anti-aging purposes. These therapies aim to enhance muscle mass, improve skin tone, and boost vitality. However, the medical community is cautious about their use. Potential risks include serious health concerns like heart disease, diabetes, and cancer. While promising, the safety of HGH in anti-aging remains under debate. Careful research and regulation are needed to ensure responsible use.
  • Scrutiny of HGH in Athletics: HGH use in sports is under increasing scrutiny. Despite its popularity among athletes and bodybuilders, studies show limited benefits for performance enhancement. Furthermore, non-prescribed use is linked to serious health risks. These include hormonal imbalances and long-term complications. Regulatory bodies are cracking down on illegal HGH usage, emphasizing the need for awareness and education about its risks.

Use Cases

  • Treatment for Growth Hormone Deficiency: HGH is prescribed for children and adults with growth hormone deficiency. In children, it helps increase growth rates, allowing them to achieve normal height. Adults with this condition may see improvements in muscle mass, energy, and bone density. The treatment enhances body composition and boosts overall quality of life. HGH therapy requires ongoing monitoring by healthcare professionals to ensure effectiveness and minimize risks.
  • Managing Turner Syndrome: Turner syndrome affects females, leading to short stature and ovarian insufficiency. HGH therapy can significantly improve height in these patients. Studies show that treatment results in an average adult height increase of 5–8 cm. Alongside other therapies, HGH helps improve overall well-being in individuals with this condition. Proper diagnosis and continuous medical supervision are essential during treatment.
  • Supporting Growth in Chronic Kidney Disease: Children with chronic kidney disease often face growth challenges. HGH therapy can help these children grow better before and after kidney transplantation. Long-term use reduces height deficits, although some loss (around 10 cm) may remain. This therapy improves their overall growth potential, helping them achieve a healthier height trajectory. Regular check-ups are crucial for evaluating the therapy’s success.
  • Assistance for Prader–Willi Syndrome: HGH is an option for treating Prader–Willi syndrome, a genetic disorder causing poor muscle tone and constant hunger. This therapy boosts growth rate, strength, and body composition in affected children. It can improve their physical agility and overall health outcomes. Early diagnosis and careful monitoring during treatment ensure the best results for these children.
  • Addressing Short Stature from Intrauterine Growth Retardation: Children born small for their gestational age may not catch up in height by age 2 or 3. HGH therapy can promote faster growth in these cases. High-dose treatments often lead to significant improvements. However, long-term benefits and risks are still under research. Close supervision by healthcare providers is necessary to track growth progress and manage side effects.
  • Treating Adult Growth Hormone Deficiency: Adults with HGH deficiency may experience reduced muscle mass, lower energy, and weaker bones. HGH replacement therapy helps restore muscle mass, improve bone density, and decrease body fat. While benefits are clear, long-term mortality improvements remain unproven. Regular medical follow-ups are important to ensure safe and effective treatment.

Conclusion

In conclusion, the Human Growth Hormone market is set to witness significant growth driven by advancements in treatments, growing awareness, and innovative drug delivery technologies. The increasing adoption of long-acting HGH formulations and rising healthcare investments, particularly in emerging economies like Asia-Pacific, are creating promising opportunities for market players. Challenges such as regulatory scrutiny and affordability concerns persist but are being addressed through ongoing innovations and collaborations among pharmaceutical companies. The market’s potential is further enhanced by the expanding application of HGH therapies in various medical conditions, supported by robust research and development efforts. These factors position the HGH market for sustained growth and innovation in the coming years.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 8+ years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.

Request a Sample Report
We'll get back to you as quickly as possible